Jounce Taps Merck Vet to Lead Cancer Drug Push

Read below for more on this story.

Jul 10, 2014 at 2:00PM

When Jounce Therapeutics launched with a big $47 million round last year, Merck (NYSE:MRK) was well behind in the race do bring the newest generation of cancer immunotherapy drugs—which harness the power of the immune system to fight tumors—to the market. Since that time, Merck has caught up to the pack. And now Jounce, which is pursuing its own ambitious cancer immunotherapy program, has nabbed one of the people responsible for that turnaround as its first full-time CEO.

Cambridge, MA-based Jounce today named Richard Murray, Merck's former senior vice president of biologics and vaccines, as its new CEO. Murray will step in for interim CEO and Third Rock Ventures partner Cary Pfeffer, who helped get Jounce off the ground last year. Pfeffer will now serve as Jounce's chairman.

Jounce CEO Richard Murray

Jounce CEO Richard Murray

Murray is taking over one of the more ambitious biotech start-ups to come out of Boston in recent years. Jounce aims to develop an unusually diverse portfolio of treatments in the hot and super competitive field of cancer immunotherapy.

Cancer immunotherapy has become perhaps the biggest battleground in life sciences after a series of key advances over the past few years. Big Pharmas like Bristol-Myers Squibb (NYSE:BMY), Merck, AstraZeneca, and several other companies have been trying to come up with and test as many combinations of so-called checkpoint inhibitors—which turn off a molecular switch that otherwise protects cancer from the immune system—as possible, hoping to find the most effective therapies. And new approaches have emerged, like so-called chimeric antigen receptor T-cell, or CAR-T technology, which seeks to use gene therapy to turn a patient's T-cells into cancer killers.

Jounce's founding idea was to combine a whole slew of cancer immunotherapy approaches into one company, and build a portfolio of different of drug candidates that work in different ways, rather than focusing on just one. The company was co-founded by Third Rock and a group of experts from MD Anderson (James Allision and Pam Sharma); the University of Chicago (Tom Gajewski); Johns Hopkins University School of Medicine (Drew Pardoll); and Georgetown University Medical Center (Louis Weiner).

Jounce hasn't yet specifically said what its targets are, but Pfeffer previously told Xconomy that the drug prospects would come from three major categories. One of those is checkpoint inhibitors like Bristol-Myers' imilimumab (Yervoy), which essentially release a brake on the immune system. Another is co-stimulatory molecules, which hit the accelerator, so to speak, boosting the immune response to cancer cells. The third category is drugs that hit molecular targets in the tumor microenvironment that make the cancer cells more or less vulnerable to the immune system.

Developing drug candidates and getting them into the clinic is the task for Murray, who was most recently tasked at Merck with helping advance protein drugs and vaccines across a variety of areas, among them cancer immunotherapy. Pfeffer said in a statement, for instance, that Murray was "instrumental" in getting Merck's checkpoint inhibitor, pembrolizumab, through clinical development. (Merck recently filed an application with the FDA to approve the drug, leapfrogging past Bristol-Myers.) Before Merck, Murray had stints at PDL Biopharma and EOS Biotechnology, which Protein Design Labs bought in 2003.

"This is a seminal time in the field of cancer immunotherapy and I am thrilled to be joining Jounce during this exciting period," said Murray, in a statement. "The company's early investment in translational science, including strategic alliances with several major academic centers, along with the active engagement of Jounce's founders, creates a unique opportunity to validate and advance the next generation of cancer immunotherapy targets and drugs."

Leaked: This coming blockbuster could make even Merck and Bristol-Myers jealous!
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

This article originally appeared on Xconomy, along with:

 Ben Fidler has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information